Danaher to acquire Aldevron in deal valued at $9.6B

By Will Morton, The Science Advisory Board contributing writer

June 17, 2021 -- Danaher announced it has signed a deal to buy DNA and messenger RNA (mRNA) manufacturer Aldevron for approximately $9.6 billion. Aldevron will operate as a standalone company in Danaher's Life Sciences business segment and is expected to boost Danaher's activities in genomic medicine.

Aldevron manufactures plasmid DNA, mRNA, and proteins, and serves biotechnology and pharmaceutical customers involved in research, clinical, and commercial applications. The privately held company is based in Fargo, ND, and employs approximately 600 people.

Rainer Blair, Danaher president and CEO, said the deal is expected to boost Danaher's activities in genomic medicine and improve the company's ability to support customers developing vaccines and other therapies, such as in cell and gene therapy.

Danaher said it expects to finance the purchase using cash on hand and proceeds from the issuance of commercial paper.

In 2020, Danaher bought GE's biopharma business.

The Aldevron purchase is subject to customary conditions, including receipt of applicable regulatory approvals, according to the company. Danaher operates more than 20 companies and a team of about 69,000 associates worldwide.

Danaher acquires Precision NanoSystems
Danaher has acquired Precision NanoSystems, a Canadian developer of genetic medicines including messenger RNA vaccines.
Cytiva acquires Vanrx Pharmasystems
Cytiva has acquired Vanrx Pharmasystems, a Canadian-based company that makes robotic aseptic filling machines to fill vials, syringes, and cartridges.
Danaher announces chief executive transition
Danaher announced on May 6 that Executive Vice President Rainer Blair will succeed Thomas Joyce Jr. as president and CEO when Joyce retires on September...
GE BioPharma sale to Danaher is complete
The divestment of GE's BioPharma business unit to Danaher is complete, according to an announcement by both companies on March 31.
FTC greenlights $20B GE-Danaher deal
Following an agreement with the U.S. Federal Trade Commission (FTC), GE Healthcare Life Sciences is moving forward with the sale of its GE Biopharma business...

Copyright © 2021 scienceboard.net

Glasgow International Health Festival
January 25-26, 2023
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter